Patent ID: 7605135

Claim:
A method for treating a subject infected with a SARS virus, said method comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound having the following formula: wherein each of X 1 , X 2 , X 3 , X 4 , X 5 , X a , X b , X c , X d , X e and X f is independently O or S; each of Y 1 , Y 2 , Y 3 , Y 4 and Y 6 is independently H or CH 3 ; each of R 4 , R 5 , R a , R b and R c is independently H, (C 1 -C 10 )alkyl optionally substituted with 1-5 R y groups, or (C 1 -C 10 )alkyl-O—(C 1 -C 10 )alkyl, each (C 1 -C 10 )alkyl of which is optionally substituted with 1-5 R y groups; each R y is independently R q or —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkynyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, (C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -phenyl, -naphthyl or —(C 14 )aryl, each of which is unsubstituted or substituted with one or more R z groups; each of R 1 , R 2 and R 3 is independently R q or (C 1 -C 10 )alkyl, —(C 2 -C 10 )alkenyl, —(C 2 -C 10 )alkenyl, —(C 3 -C 10 )cycloalkyl, —(C 8 -C 14 )bicycloalkyl, —(C 8 -C 14 )tricycloalkyl, —(C 5 -C 10 )cycloalkenyl, (C 8 -C 14 )bicycloalkenyl, —(C 8 -C 14 )tricycloalkenyl, -phenyl, -naphthyl or —(C 14 )aryl, each of which is unsubstituted, substituted with one or more R q groups, substituted with one or more R z groups, or substituted with one or more R q groups and one or more groups; R f is H, (C 1 -C 12 )alkyl optionally substituted with 1-5 R y groups, (C 1 -C 12 )alkyl-O—(C 1 -C 12 )alkyl, each (C 1 -C 12 )alkyl of which is optionally substituted with 1-5 R y , or a counterion; each R q is independently CN, OH, halo, N 3 , NO 2 , N(R z ) 2 ═NR z , CH═NR z , NR z OH, OR z , COR z , C(O)OR z , OC(O)R z , OC(O)R z , OC(O)OR z , SR z , S(O)R z or S(O)2R z ; each R z is independently —(C 1 -C 6 )alkyl, —(C 2 -C 6 )alkenyl, (C 2 -C 6 )alkenyl, (C 3 -C 8 )cycloalkyl, —(C 5 -C 8 )cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, C(halo) 3 or CH(halo) 2 ; and n is 0, 1, 2, 3, 4, or 5 and/or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier and/or excipient, wherein said compound is at least 95% pure.